Brown Advisory Inc. lessened its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 2.7% during the third quarter, Holdings Channel reports. The institutional investor owned 93,857 shares of the medical equipment provider’s stock after selling 2,608 shares during the quarter. Brown Advisory Inc.’s holdings in Hologic were worth $3,846,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Piedmont Investment Advisors LLC bought a new stake in shares of Hologic during the second quarter valued at approximately $127,000. Bessemer Group Inc. raised its holdings in shares of Hologic by 122.4% during the third quarter. Bessemer Group Inc. now owns 3,534 shares of the medical equipment provider’s stock valued at $145,000 after buying an additional 1,945 shares during the last quarter. Amussen Hunsaker Associates LLC bought a new stake in shares of Hologic during the second quarter valued at approximately $159,000. Stratos Wealth Partners LTD. bought a new stake in shares of Hologic during the third quarter valued at approximately $185,000. Finally, Lincoln Capital Corp bought a new stake in shares of Hologic during the third quarter valued at approximately $201,000. 91.73% of the stock is currently owned by institutional investors.
A number of equities research analysts have recently weighed in on HOLX shares. Needham & Company LLC reaffirmed a “buy” rating and set a $48.00 price target on shares of Hologic in a report on Thursday, September 27th. BidaskClub raised Hologic from a “hold” rating to a “buy” rating in a report on Thursday, October 11th. TheStreet cut Hologic from a “b-” rating to a “c+” rating in a report on Wednesday, September 5th. Barclays cut Hologic from an “overweight” rating to an “equal weight” rating and cut their price target for the company from $50.00 to $43.00 in a report on Wednesday, September 5th. They noted that the move was a valuation call. Finally, Morgan Stanley cut their price target on Hologic from $47.00 to $44.00 and set an “equal weight” rating on the stock in a report on Thursday, October 11th. Eleven equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Hologic presently has a consensus rating of “Hold” and a consensus target price of $44.53.
In related news, Director Christiana Stamoulis sold 30,967 shares of the business’s stock in a transaction that occurred on Tuesday, October 2nd. The stock was sold at an average price of $40.70, for a total transaction of $1,260,356.90. Following the sale, the director now owns 66,006 shares of the company’s stock, valued at $2,686,444.20. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Sally Crawford sold 13,257 shares of the business’s stock in a transaction that occurred on Monday, September 17th. The stock was sold at an average price of $39.54, for a total value of $524,181.78. Following the sale, the director now directly owns 167,701 shares in the company, valued at approximately $6,630,897.54. The disclosure for this sale can be found here. In the last three months, insiders have sold 79,276 shares of company stock worth $3,311,802. 0.88% of the stock is owned by corporate insiders.
Shares of NASDAQ:HOLX opened at $43.90 on Thursday. Hologic, Inc. has a 12 month low of $35.10 and a 12 month high of $45.17. The company has a market cap of $12.84 billion, a P/E ratio of 19.69, a PEG ratio of 2.07 and a beta of 0.69. The company has a current ratio of 1.23, a quick ratio of 0.95 and a debt-to-equity ratio of 1.12.
Hologic (NASDAQ:HOLX) last announced its earnings results on Wednesday, November 7th. The medical equipment provider reported $0.58 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.59 by ($0.01). Hologic had a positive return on equity of 23.52% and a negative net margin of 3.46%. The firm had revenue of $813.50 million for the quarter, compared to the consensus estimate of $808.63 million. During the same period in the previous year, the firm earned $0.50 EPS. Hologic’s revenue for the quarter was up 1.3% on a year-over-year basis. As a group, analysts anticipate that Hologic, Inc. will post 2.4 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This story was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright law. The legal version of this story can be read at https://www.dispatchtribunal.com/2018/12/06/hologic-inc-holx-stake-decreased-by-brown-advisory-inc.html.
Hologic Company Profile
Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. The company operates through five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.
Further Reading: Bull Market
Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.